Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin

J Antimicrob Chemother. 2000 Aug;46(2):241-7. doi: 10.1093/jac/46.2.241.

Abstract

The efficacy of an antibiotic in the treatment of bacterial infections depends upon the interaction of bacterium, drug and phagocytes. In this study we have investigated the influence of AF3013, a new fluoroquinolone, on the activities of mouse peritoneal macrophages against Klebsiella pneumoniae, in comparison with the influence of pefloxacin. Bacterial susceptibility to phagocytosis and intracellular killing were determined after klebsiellae and macrophages had been incubated simultaneously with inhibitory concentrations of both AF3013 and pefloxacin and following pre-exposure of the microorganisms and the macrophages individually to the same concentrations of each drug. Under the experimental conditions used, both AF3013 and pefloxacin potentiated the phagocytic and microbicidal activities of the macrophages, although different mechanisms may be involved.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology*
  • Cell Survival / drug effects
  • Dioxolanes / pharmacology*
  • Fluoroquinolones*
  • In Vitro Techniques
  • Klebsiella pneumoniae / drug effects*
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / immunology*
  • Male
  • Mice
  • Microbial Sensitivity Tests
  • Pefloxacin / pharmacology*
  • Phagocytosis / drug effects
  • Piperazines / pharmacology*
  • Quinolones / pharmacology*

Substances

  • AF 3013
  • Anti-Infective Agents
  • Dioxolanes
  • Fluoroquinolones
  • Piperazines
  • Quinolones
  • Pefloxacin
  • prulifloxacin